Bone Biologics
BBLG
3 hedge funds and large institutions have $4.85K invested in Bone Biologics in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 4 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
2.6% less ownership
Funds ownership: 2.84% → 0.25% (-2.6%)
57% less funds holding
Funds holding: 7 → 3 (-4)
93% less capital invested
Capital invested by funds: $74.1K → $4.85K (-$69.2K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.03K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$34.2K |
| 2 |
Two Sigma Investments
New York
|
-$16.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$15.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.6K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$20 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
1
Tower Research Capital (TRC)
New York
| $4.54K | +$1.03K | +747 | +22% |
|
|
SS
2
SBI Securities
Tokyo,
Japan
| $253 | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $62 | -$2.6K | -1,892 | -97% |
|
|
DS
4
DRW Securities
Chicago,
Illinois
| – | -$34.2K | -23,576 | Closed |
|
|
5
Two Sigma Investments
New York
| – | -$16.1K | -11,083 | Closed |
|
|
6
Citadel Advisors
Miami,
Florida
| – | -$15.7K | -10,844 | Closed |
|
|
7
Bank of America
Charlotte,
North Carolina
| – | -$20 | -14 | Closed |
|
BBLG Hedge Fund Activity: Q1 2026 in Review
3 of the 8,146 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics (BBLG) for Q1 2026, worth a combined $4.85K — down 93% from $74.1K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BBLG and 0 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $1.03K. The largest seller was DRW Securities, exiting entirely with an estimated $34.2K sold.
- 3 institutional investors held Bone Biologics (BBLG) as of Q1 2026, down from 7 in Q4 2025.
- Funds reported $4.85K of Bone Biologics stock for Q1 2026, down 93% quarter-over-quarter.
- 0 funds opened new Bone Biologics positions in Q1 2026 and 4 closed out, a net change of -4 holders.
- The largest Bone Biologics buyer in Q1 2026 was Tower Research Capital (TRC), an estimated $1.03K added.
- The largest Bone Biologics seller in Q1 2026 was DRW Securities, an estimated $34.2K sold.
Based on aggregated 13F filings for Q1 2026.